摘要
目的:系统评价补肾解毒法联合抗病毒治疗慢性乙型病毒性肝炎(简称乙型肝炎)(Chronic Hepatitis B,CHB)的临床疗效。方法:计算机检索中、英文数据库,搜索关于补肾解毒法联合抗病毒治疗CHB的临床随机对照研究,检索时限为建库至2021年4月,两名研究者进行文献筛选和资料提取,根据Cochrane偏倚风险评价工具进行文献质量评价,应用RevMan 5.3软件进行统计分析。结果:共纳入11项随机对照试验,971例CHB患者。试验组治疗CHB的临床疗效有效率、中医证候改善率均优于对照组;与对照组相比,在治疗4周时,试验组的丙氨酸转氨酶水平显著下降;在治疗24周、48周时,试验组对增加乙型肝炎病毒脱氧核糖核酸(Hepatitis B Virus-Deoxyribonucleic Acid,HBV-DNA)转阴率、乙型肝炎病毒E抗原血清学转换率具有明显优势;在治疗48周时,试验组的丙氨酸转氨酶复常率高于对照组,差异有统计学意义(P<0.05)。结论:补肾解毒法联合抗病毒治疗慢性CHB的疗效优于单纯抗病毒治疗,但仍需开展更多大样本的高质量随机对照试验加以验证。
Objective:To systematically evaluate the clinical efficacy of the Bushen Jiedu therapy(补肾解毒法)plus antiviral therapy on chronic hepatitis B.Methods:The Chinese and English databases were searched by computer,and the self-built databases were collected until April 2021.The clinical randomized controlled studies on the intervention of the Bushen Jiedu therapy plus antiviral therapy on chronic hepatitis B were collected.Two investigators conducted literature screening and data extraction,evaluated the quality of the included RCTs by the tool of bias risk evaluation of Cochrane,and then used RevMan 5.3 software for data analysis.Results:A total of 11 RCTs and 971 patients with CHB were included.The experimental group were superior to the control group in increasing the clinical efficiency and the TCM syndromes improvement rate.Compared with the control group,the ALT level in the experimental group were lower at 4 weeks of treatment;the experimental group were more advantageous in increasing HBV-DNA negative conversion rate,HBeAg serological conversion rate at 24,48 weeks of treatment and ALT normalization rate at 48 weeks of treatment,and the differences were statistically significant(P<0.05).Conclusion:The Bushen Jiedu therapy plus antiviral therapy is better than antiviral therapy alone in the treatment of CHB,but it still needed to be further verified by high-quality large samples of RCTs.
出处
《中医临床研究》
2022年第11期138-143,共6页
Clinical Journal Of Chinese Medicine
基金
湖南省自然科学基金(2019JJ50470)
国家自然科学基金(81704068)
湖南中医药大学中医学国内一流建设学科。
